Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

The anti-CD20 monoclonal antibodies rituximab and obinutuzumab differ in their mechanisms of action, with obinutuzumab evoking greater direct B cell death. To characterize the signaling processes responsible for improved B cell killing by obinutuzumab, we undertook a phosphoproteomics approach and d...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:iScience
Main Authors: Edelmann, Jennifer, Dokal, Arran D., Vilventhraraja, Emma, Holzmann, Karlheinz, Britton, David, Klymenko, Tetyana, Döhner, Hartmut, Cragg, Mark, Braun, Andrejs, Cutillas, Pedro, Gribben, John G.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7878992/
https://ncbi.nlm.nih.gov/pubmed/33615197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.isci.2021.102089
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares